{
    "clinical_study": {
        "@rank": "6730", 
        "arm_group": {
            "arm_group_label": "Dabigatran"
        }, 
        "brief_summary": {
            "textblock": "This study is being conducted to collect data on the management of major bleeding events\n      occurring in patients with atrial fibrillation taking dabigatran etexilate."
        }, 
        "brief_title": "Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Atrial Fibrillation", 
            "Hemorrhage"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atrial Fibrillation", 
                "Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "Purpose:"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Greater than or equal to 18 years of age;\n\n          -  Confirmed diagnosis of non valvular atrial fibrillation (NVAF) (Diagnosis of AF is\n             considered confirmed if there is medical chart documentation that the patient has\n             atrial fibrillation or AF or the ICD-9 or ICD-10 code for AF is documented);\n\n          -  NVAF is defined as follows:  nonvalvular atrial fibrillation is restricted to cases\n             in which the rhythm disturbance occurs in the absence of rheumatic mitral stenosis or\n             a prosthetic heart valve.\n\n          -  Documentation that the patient presented to an emergency department/emergency room\n             (ED/ER) for a major bleeding event (index event);\n\n          -  Major bleeding is defined by International Society on Thrombosis and Haemostasis\n             (ISTH) as:\n\n          -  fatal bleeding and/or\n\n          -  symptomatic bleeding in a critical area/organ such as intracranial, intraspinal,\n             intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with\n             compartment syndrome, and/or\n\n          -  bleeding causing a fall in hemoglobin of 20g per liter or more, or leading to\n             transfusion of 2 or more units of whole blood or red blood cells\n\n          -  Documentation that the index event occurred in a patient who reported having taken at\n             least one dose of dabigatran within the 5 days prior to the index event.\n\n        Exclusion criteria:\n\n          -  Confirmed diagnosis of valvular AF (Diagnosis of valvular AF is considered confirmed\n             if there is medical chart documentation that the patient has valvular AF or VAF. In\n             the absence of documentation to indicate whether the patient has non-valvular or\n             valvular AF,);\n\n          -  Documentation that the patient was taking dabigatran with a concomitant anticoagulant\n             (contemporaneous parenteral anticoagulant or another oral anticoagulant) within 72\n             hours of the index event;\n\n          -  The concomitant administration of antiplatelet medications prior to the onset of the\n             index event is not exclusionary;\n\n          -  Documentation of the patient receiving thrombolytic therapy within 48 hours of the\n             onset of the index event;\n\n          -  Documentation that the patient was enrolled in an interventional investigational or\n             other BI observational clinical trial at the time of the onset of the index event;\n\n          -  Medical record was not retrievable, was missing or empty."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "AF patients with bleeding event using Dabigatran etexilate"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02149303", 
            "org_study_id": "1160.200"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dabigatran", 
                "description": "PO BID", 
                "intervention_name": "Dabigatran 75 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dabigatran", 
                "description": "PO BID", 
                "intervention_name": "Dabigatran 150 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "1160.200.02 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "1160.200.06 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri"
                    }, 
                    "name": "1160.200.04 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brooklyn", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "1160.200.01 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stony Brook", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "1160.200.05 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas"
                    }, 
                    "name": "1160.200.03 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of patients with index event safety outcomes (ongoing/resolved/deceased)", 
                "safety_issue": "No", 
                "time_frame": "at time of hospital discharge/release with an average hospital stay of approximately 9 days"
            }, 
            {
                "measure": "Number of patients receiving different types of interventions to stop the index events", 
                "safety_issue": "No", 
                "time_frame": "until hospital discharge/release with an avergae hospital stay of approximately 9 days"
            }, 
            {
                "measure": "Frequencies of bleeding types and anatomic locations of the index event", 
                "safety_issue": "No", 
                "time_frame": "at time presentation or hospitalization, day 1"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02149303"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}